Granahan Investment Management Reduces Stake in Viking Therapeutics

Firm sells over 115,000 shares of biotech company's stock

Mar. 16, 2026 at 10:38am

Got story updates? Submit your updates here. ›

Granahan Investment Management LLC decreased its stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) by 37.9% during the 3rd quarter, according to the company's recent disclosure with the Securities & Exchange Commission. The fund now owns 189,529 shares of the biotechnology company's stock, down from 305,091 shares previously.

Why it matters

This filing provides insight into the investment decisions of Granahan Investment Management, a notable institutional investor in Viking Therapeutics. The reduction in stake could signal a shift in the firm's outlook on the biotech company's prospects.

The details

Granahan Investment Management sold 115,562 shares of Viking Therapeutics stock during the 3rd quarter, reducing its position to 189,529 shares. The firm now owns about 0.17% of the biotechnology company's outstanding shares, down from 0.27% previously.

  • Granahan Investment Management decreased its stake in Viking Therapeutics during the 3rd quarter of 2026.

The players

Granahan Investment Management LLC

An investment management firm that previously held a sizable stake in Viking Therapeutics.

Viking Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Granahan Investment Management's position in Viking Therapeutics could signal a shift in investor sentiment around the biotech company's prospects, though the reasons behind the firm's decision are not entirely clear from the filing.